Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Nabi (NABI) -- Ignore unavailable to you. Want to Upgrade?

To: peter a. pedroli who wrote (256)	10/12/1999 2:02:00 PM
From: Ken M	Read Replies (1) \| Respond to of 354

(COMTEX) B: NABI(R) RECEIVES PATENTS ON STAPHYLOCOCCUS EPIDERMIDIS VA B: NABI(R) RECEIVES PATENTS ON STAPHYLOCOCCUS EPIDERMIDIS VACCINE AND IMMUNE GLOBULIN BOCA RATON, Fla., Oct 12, 1999 /PRNewswire via COMTEX/ -- Nabi (Nasdaq: NABI) announced that it has been issued two patents (US Pat. No. 5,866,140 & 5,961,975) containing claims covering both a Staphylococcus epidermidis vaccine and a hyperimmune globulin made using the vaccine. S. epidermidis is a ubiquitous species of Gram-positive bacteria. Dr. Robert Naso, Sr. Vice President at Nabi, was quoted as saying, "The issuance of these patents has significantly strengthened our proprietary position around the staphylococcal vaccines and immunoglobulin products we currently have in development. It is our strategy to integrate these antigens into pharmaceutical products aimed at preventing and treating life-threatening bacterial infections." Staphylococci cause approximately two-thirds of hospital-acquired bacteremias, and these infections are a leading cause of hospital mortality in the United States. Morbidity and mortality caused by S. epidermidis are especially high in patients requiring prosthetic medical devices such as catheters and heart valves. As is the case with Staphylococcus aureus, S. epidermidis has shown increasing resistance to currently available antibiotics including vancomycin. Nabi has demonstrated in pre-clinical models, that antibodies to the S. epidermidis vaccine described in the issued patents are able to provide significant protection against challenge with clinical isolates of this bacterium. The first generation staphylococcal vaccine being developed by Nabi is Nabi-StaphVAX(R), a vaccine for the prevention of S. aureus infections, which is currently in Phase III clinical development. Positive interim results from this pivotal trial were reported recently (Nabi press release dated August 25, 1999). A second-generation vaccine addressing both S. aureus and S. epidermidis infections is in pre- clinical development by Nabi. Nabi, a fully integrated biopharmaceutical company, has a broad product portfolio and significant R&D capabilities focused on the development and commercialization of drugs that prevent and treat infectious and autoimmune diseases. Nabi currently has several clinical trials underway in these areas and has four marketed pharmaceutical products. Additional information may be obtained on the Company's web site at www.nabi.com. This press release may contain forward-looking statements that reflect the Company's current expectations regarding future events. While these statements reflect the Company's best current judgment, they are subject to risks and uncertainties. Actual results may differ significantly from the results projected herein due to a number of factors, including, but not limited to, the impact on the Company of current industry supply and demand factors and the supply of and demand for the Company's individual products; margin pressure on the Company's non-specific antibody product line; future sales growth prospects for its pharmaceutical products; the likelihood that any product in the research pipeline can receive regulatory approval in the U.S. or abroad or be successfully developed, manufactured and marketed; failure to receive licensure for the Boca Raton manufacturing facility; and dependence upon third parties to manufacture product. These factors are more fully discussed in the Company's most recent Form 10-K filed with the Securities and Exchange Commission. SOURCE Nabi (C) 1999 PR Newswire. All rights reserved. prnewswire.com -0- CONTACT: Tanina Frouge, Director, Investor Relations of Nabi, 561-989-5815 WEB PAGE: nabi.com GEOGRAPHY: Florida INDUSTRY CODE: MTC SUBJECT CODE: LIC * end of story *